MOLCURE Inc., (Kanagawa, Japan; CEO: Ryu Ogawa; “MOLCURE”) today announced that it has entered into a drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; “Ono”), to discover and develop innovative antibody drugs for multiple targets utilizing MOLCURE’s AI-driven platform technology.

Under the terms of the agreement, MOCLURE will discover and identify antibodies or molecules for multiple targets of interest selected by Ono, using MOLCURE’s proprietary AI-driven platform technology. Ono will obtain option rights to exclusively and globally develop and commercialize therapeutic antibody drug candidates generated through the collaboration. Ono will pay to MOLCURE an upfront payment and research funding, and success-based milestone payments on research, development and commercialization, as well as tiered royalties based on global net sales.

“We are actively working to create biologics like antibodies in order to address unmet medical needs. We appreciate MOLCURE’s AI-driven platform technology which enables us to design functional antibodies for targets that are difficult to generate with conventional technologies and are pleased to have the opportunity to collaborate with MOLCURE,” said Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research of Ono. “We believe that this new collaboration will accelerate our biologics drug discovery efforts and bring innovative drugs for patients as soon as possible.”

“We are delighted that Ono has recognized MOLCURE’s capabilities by choosing to partner with us.” said Dr. Ryu Ogawa, CEO of MOLCURE. “This is an exciting opportunity to use our AI-driven platform to help Ono accelerate and maximize its antibody drug discovery program. We hope that our partnership will give rise to innovative drugs that will improve the lives of patients around the world.” 

About MOLCURE Inc.
MOLCURE was founded in 2013 with a mission to build the best platform for biologics discovery in the world. Today, its platform integrates AI with evolutionary molecular engineering, next-generation sequencing, laboratory automation technologies, and a proprietary database containing more than one billion molecular entries. These capabilities enable the delivery of diverse, high affinity, specific and functional antibodies and peptides for researchers. MOLCURE is partnering with innovative companies to discover therapeutics with the potential to benefit patients around the world.

<Corporate Information>
Company Name: MOLCURE Inc.
CEO: Ryu Ogawa
Head Office Address: AIRBIC A07, 7-7 Shinkawasaki, Saiwai-ku, Kawasaki City, Kanagawa, Japan

<For media and service inquiries>
Email: contact[@]